Publication at First Faculty of Medicine |
2014
Abstract
Liraglutide is a synthetic GLP-1 agonist that shares close homology with native GLP-1. Long half-life of liraglutide enables its administration once daily.
The aim of this paper is to summarize experimental and clinical data related to use of liraglutide in the treatment of type 2 diabetes mellitus. We will also briefly discuss extrapancreatic effects of liraglutide and future perspective of its use not only in patients with type 2 diabetes mellitus but also in non-diabetics.